Pharmacokinetic modeling of 48 patients showed that tumor uptake of Lu-177 DOTATATE decreases with each PRRT cycle — dropping to 87%, 80%, and 78% of first-cycle levels in cycles 2, 3, and 4 respectively.
77.6% uptake by cycle 4Tumor absorption of Lu-177 DOTATATE decreases progressively but plateaus, challenging the receptor downregulation hypothesis
What the researchers found
Tumor uptake of Lu-177 DOTATATE decreased progressively: 86.9% (cycle 2), 79.7% (cycle 3), and 77.6% (cycle 4) of first-cycle levels. The plateau pattern suggests receptor downregulation is likely not the primary cause.
Why it matters
Understanding why tumors absorb less radiation over treatment cycles is critical for optimizing PRRT dosing. If clinicians know the expected reduction, they may adjust doses, combine therapies, or time cycles differently to maximize treatment effectiveness.
The numbers in context
48 patients with multiple PRRT cycles. Five-compartment pharmacokinetic model used.
How the study worked
Population pharmacokinetic model using imaging data from 48 patients receiving multiple Lu-177 HA-DOTATATE cycles. Five-compartment model (central, kidney, spleen, tumor, rest). Evaluated tumor volume and SSA use as covariates.
Who was studied
48 patients receiving multiple cycles of 177Lu-HA-DOTATATE PRRT
What this study cannot tell us
Retrospective modeling from a single center. Used imaging-derived uptake data which has inherent measurement variability. The study used Lu-177 HA-DOTATATE (a specific formulation), and results may not perfectly transfer to other DOTATATE preparations. The cause of the cycle effect remains uncertain.
How to read the evidence
Moderate evidence from pharmacokinetic modeling of 48 patients. Robust methodology but based on single-center data with inherent imaging measurement limitations.
When this study was published
Published in 2024. Addresses a clinically important gap in PRRT dosimetry optimization.
The bigger picture
As PRRT becomes standard care for neuroendocrine tumors, quantifying treatment dynamics becomes essential for personalized dosimetry. This finding challenges the assumption of constant tumor uptake across cycles and could lead to individualized treatment planning based on predicted cycle-specific uptake.
Questions still open
- Should PRRT dosing be increased in later cycles to compensate for reduced tumor uptake?
- What is the biological mechanism driving the uptake plateau in cycle 4?
- Could combining PRRT with somatostatin receptor upregulators restore first-cycle uptake levels?
Common questions
Why does the tumor absorb less radiation with each treatment?
Does reduced uptake mean later treatment cycles are less effective?
Read the original research
The cycle effect quantified: reduced tumour uptake in subsequent cycles of [177Lu]Lu-HA-DOTATATE during peptide receptor radionuclide therapy.
European journal of nuclear medicine and molecular imaging, 51(3), 820-827
Citation
Siebinga, H; Hendrikx, J J M A; de Vries-Huizing, D M V; Huitema, A D R; de Wit-van der Veen, B J. (2024). The cycle effect quantified: reduced tumour uptake in subsequent cycles of [177Lu]Lu-HA-DOTATATE during peptide receptor radionuclide therapy.. European journal of nuclear medicine and molecular imaging, 51(3), 820-827. https://doi.org/10.1007/s00259-023-06463-2